Adaptive Biotechnologies Corporation
ADPT · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.15 | 0.71 | -1.44 | 0.20 |
| FCF Yield | -0.74% | -2.68% | -1.42% | -3.63% |
| EV / EBITDA | -99.93 | -38.67 | -35.11 | -32.93 |
| Quality | ||||
| ROIC | -6.04% | -6.83% | -7.49% | -6.79% |
| Gross Margin | 69.43% | 67.62% | 61.98% | 64.11% |
| Cash Conversion Ratio | -0.75 | 0.49 | 0.95 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.04% | 2.67% | 0.93% | -1.16% |
| Free Cash Flow Growth | 56.01% | -136.60% | 54.14% | -44.02% |
| Safety | ||||
| Net Debt / EBITDA | -2.27 | -1.22 | -1.58 | -2.19 |
| Interest Coverage | -8.49 | -10.19 | -11.46 | -11.10 |
| Efficiency | ||||
| Inventory Turnover | 2.14 | 1.96 | 2.14 | 1.39 |
| Cash Conversion Cycle | 75.17 | 87.10 | 85.00 | 103.97 |